Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Capital Expenditures (2017 - 2025)

Cue Biopharma's Capital Expenditures history spans 8 years, with the latest figure at $27000.0 for Q2 2025.

  • For Q2 2025, Capital Expenditures rose 170.0% year-over-year to $27000.0; the TTM value through Sep 2025 reached $179000.0, up 179.69%, while the annual FY2024 figure was $66000.0, N/A changed from the prior year.
  • Capital Expenditures for Q2 2025 was $27000.0 at Cue Biopharma, down from $150000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $648000.0 in Q1 2021 and bottomed at -$1000.0 in Q3 2024.
  • The 4-year median for Capital Expenditures is $27000.0 (2022), against an average of $94788.5.
  • The largest annual shift saw Capital Expenditures plummeted 99.96% in 2021 before it surged 2464.1% in 2022.
  • A 4-year view of Capital Expenditures shows it stood at $39.0 in 2021, then soared by 2464.1% to $1000.0 in 2022, then skyrocketed by 100.0% to $2000.0 in 2024, then soared by 1250.0% to $27000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Capital Expenditures are $27000.0 (Q2 2025), $150000.0 (Q1 2025), and $2000.0 (Q4 2024).